In the NeoSphere study, patients with operable, locally advanced, or inflammatory HER2-positive breast cancer received neoadjuvant docetaxel/trastuzumab/pertuzumab (DTP) therapy, with the primary endpoint being the achievement of a pathologic complete response (pCR). The gene discussed is ERBB2; the disease is breast carcinoma.